In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, CRH Medical (TSX: CRH). Analyst Lennox Gibbs from TD Securities remains bullish on the stock and has a C$6.50 price target.
According to TipRanks.com, Gibbs is ranked #4120 out of 4872 analysts.
Read also: INSYS Therapeutics (INSY) Stock Fires on All Cylinders; Here’s Why
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CRH Medical with a C$5.50 average price target, implying a 1.7% upside from current levels. In a report issued on August 21, National Bank also maintained a Buy rating on the stock with a C$5.75 price target.
.
CRH Medical’s market cap is currently C$393.2M and has a P/E ratio of 37. The company has a Price to Book ratio of 4.21.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Tuesday at C$5.41, close to its 52-week high of C$5.57.
